J Pharm Sci 1994;83:1081-4
4C) did not detect statistically significant alterations in microglial morphology in animals with MetS treated with semaglutide (HFD SEMA), indicating that semaglutide cannot reverse the microglial activation profile in the MeS
Subgroup analyses by BMI, HbA1c, and GFR indicated consistent trends of lower risk
For women managing PCOS, navigating perimenopause, carrying cardiovascular risk, or dealing with chronic migraine, or dealing with the metabolic consequences of hormonal change, Wegovy addresses biology that has historically been underdiscussed and undertreated
Consistent daily dosing throughout the cycle produces better results than sporadic use
Healthy habits are still key Even with strong appetite control, long-term success depends on sustainable eating patterns, regular movement and stress management